Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD MGNX
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Completes Acquisition of MiroBio
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Acquire MiroBio
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Announces Second Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.